Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: A report from the Children's Cancer Group

Journal of Clinical Oncology

Volumn 15, Issue 8, 1997, Pages 2780-2785

  Dinndorf, Patricia A ^a   Avramis, Vassilios I ^a   Wiersma, Susan ^a   Krailo, Mark D ^a   Liu Mares, Wen ^a   Seibel, Nita L ^a   Sato, Judith K ^a   Mosher, Revonda B ^a   Kelleher, John F ^a   Reaman, Gregory H ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTARABINE; FLUDARABINE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; INFANT; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MALE; MULTICENTER STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; VOMITING;

EID: 0030762650     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.8.2780     Document Type: Article

References (17)

1. Wiernik PH, Glidewell OJ, Hoagland HC, et al: A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia. Med Pediatr Oncol 6:261-277, 1979
2. Pui, C-H: Childhood leukemias. N Engl J Med 332:1618-1630, 1995
3. Berman E, Wittes RE, Leyland-Jones B, et al: Phase I and clinical pharmacology studies of intravenous and oral administration of 4 demethoxydaunorubicin in patients with advanced cancer. Cancer Res 43:6090-6101, 1983
4. Wiernik PH, Banks PLC, Case DC, et al: Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79:313-319, 1992
5. Wiernik PH, Case DC, Periman PO, et al: A multicenter trial of cytarabine plus idarubicin or daunorubicin as induction therapy for adult nonlymphocytic leukemia. Semin Oncol 16:25-29, 1989
6. Berman E, Heller G, Santorsa J, et al: Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666-1674, 1991
7. Berman E, Raymond V, Gee T, et al: Idarubicin in acute leukemia: Results of studies at Memorial Sloan-Kettering Cancer Center. Semin Oncol 16:30-34, 1989
8. Vogler WR, Velez-Garcia E, Omura G, et al: A. phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabino-side in acute myelogenous leukemia. Semin Oncol 16:21-24, 1989
9. Gandhi V, Plunkett W: Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 48:329-334, 1988
10. Gandhi V, Estey E, Keating MJ, et al: Biochemical modulation of arabinosyl-cytosine for therapy of leukemias. Leukemia Lymphoma 10:109-114, 1993 (suppl)
11. Gandhi V, Kemena A, Keating MJ, et al: Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chrome lymphocytic leukemia. Cancer Res 52:897-903, 1992
12. Avramis VI, Champagne J, Sato J, et al: Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res 50:7226-7231, 1990
13. Avramis VI, Huang SH, Holcenberg JS: Drug synergism, antagonism and collateral sensitivity involving genetic changes, in Chou TC, Rideout DC (eds): Molecular Mechanisms of Chemotherapeutic Synergism, Potentiation, and Antagonism. Orlando, FL, Academic, 1991, pp 585-619
14. Avramis VI, Wiersma S, Cheng A, et al: Selective pharmacological synergism between F-araA and ara-C in human leukemic cells in vitro and in vivo. Proc Am Soc Clin Oncol 8:215, 1989 (abstr 835)
15. Sato JK, Wiersma S, Krailo M, et al: Phase I and pharmacodynamic study of continuous infusion (CI) fludarabine followed by continuous infusion (CI) cytosine arabinoside (ara-C) in relapsed leukemia. Proc Am Assoc Cancer Res 33:211, 1992 (abstr 1266)
16. Bishop YMM, Feinberg SE, Holland PMW: Discrete Multivariate Analysis. Cambridge, MA, MIT Press, 1975
17. Reid JM, Pendergrass TW, Krailo MD, et al: Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: A Childrens Cancer Study Group report. Cancer Res 50:6525-6528, 1990